Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | DDR1 | Q08345 | 7/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.36 |
| ▸ | ITGAV | P06756 | 1/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.35 |
| ▸ | SFRP1 | Q8N474 | 2/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | VDR | P11473 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6500429 | 0.92 | ITGB3 (0.36) | DRD2DRD3DDR1ITGB3ITGAV | |
| SCHEMBL6499244 | 0.90 | CNR1 (0.38) | DRD2DRD3ITGB3ITGAVITGA2B | |
| SCHEMBL383158 | 0.90 | ITGB3 (0.44) | DRD2DRD3ITGB3ITGAVITGA2B | |
| SCHEMBL6501603 | 0.87 | RORC (0.37) | DRD2DRD3ITGB3ITGAVITGA2B | |
| SCHEMBL383252 | 0.86 | CASR (0.42) | ITGB3ITGAVITGA2BMCHR1 | |
| SCHEMBL383350 | 0.86 | CASR (0.42) | ITGB3ITGAVITGA2BMCHR1 | |
| SCHEMBL7469399 | 0.86 | SFRP1 (0.40) | DRD2DRD3DDR1ITGB3ITGAV | |
| SCHEMBL382456 | 0.85 | ITGB3 (0.47) | ITGB3ITGAVITGA2BMCHR1ADRA2A | |
| SCHEMBL6497814 | 0.85 | ITGB3 (0.41) | DRD2DRD3ITGB3ITGAVITGA2B | |
| SCHEMBL383095 | 0.84 | ITGB3 (0.46) | DRD2DRD3ITGB3ITGAVITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059669-A1 | M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity | AJITO KEIICHI (JP) | 2005-03-17 | — | — | US | claimed |
| US-20050059669-A1 | M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity | AJITO KEIICHI (JP) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059669-A1 | M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity | ITGAV, ITGB3, ITGA4 | DRD2 796/4885DRD3 514/4885DDR1 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.